Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU

SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA as expected: ↘️disease activity ↘️pain and function ↘️QoL at 14 wks no new safety alerts https://t.co/2efpx7Mi6i

Interesting, NWA by Dougados et al shows both Tofa and ADA may benefit pain in those who have controlled inflammatory component. ?real effect vs imperfect measures @RheumNow #EULAR2022 OP0052 https://t.co/aYBTaSDa3v https://t.co/dkLv1l5tFy

• EULAR Abstract Archive

Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF

• EULAR Abstract Archive

#Bestinclass #EULAR2022 #PsA @RheumNow #OP0027 #CVE #MACE with #Tofacitinib in #psoriatic #arthritis and #PsO with median 3 to 4 yrs Rx. 40% metabolic syndrome which is high. There was no comparison. As expected hose with ⬆️MACE risks had more outcomes. https://t.co/sTjFHsUxzi

#EULAR2022 POS0241 shows JAKi ⬇️ pain catastrophization/central sensitization in RA patient via CSI (Central Sensitization Inventory) and (PCS) Pain Catastrophizing Scale. No decrease of articular inflammation on ultrasound with JAKi shown, but study had just 22 pts @RheumNow

@Rheumnow #EULAR2022 POS0240 ▶️ In 2021, 73.6% of Belgian RA patients staring a JAKi, started a 2nd generation JAKi (UPA, FIL). Predictors for 1st generation usage (BAR, TOFA): older age, prior DMARD therapies. What would you start as a first JAKi?

#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI

After the #EULAR2022 Recommendations session, it begs the question - Do we follow it? In Germany, the answer is sometimes Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD POS0234 @Rheumnow https://t.co/0DaP5b7Htc